Literature DB >> 15784129

A chronic myeloid leukemia-like syndrome case with del (12) (p12) in a Li-Fraumeni syndrome family.

S Guran1, C Beyan, O Nevruz, C Yakicier, Y Tunca.   

Abstract

Li-Fraumeni syndrome is a familial cancer syndrome characterized by different tumors and hereditary p53 mutations. Here, a chronic myeloid leukemia-like syndrome case in a Li-Fraumeni syndrome family with del (12) (p12) cytogenetic abnormality was presented. A hereditary p53 mutation (pro309ser) supported the Li-Fraumeni syndrome diagnosis in this family. This syndrome was characterized by the clonal myeloproliferative accumulation in bone marrow and peripheral blood with negative bcr/abl gene rearrangement finding. The etiology of this rare syndrome is still unclear. This is the only chronic myeloid leukemia-like syndrome case reported in a Li-Fraumeni syndrome family. Del (12)(p12) was observed in leukemias except chronic myeloid leukemia-like syndrome. The deletion in chromosome 12p12 with hereditary p53 mutation should have a critical role in chronic myeloid leukemia-like syndrome etiology in our case.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784129     DOI: 10.1111/j.1365-2257.2005.00679.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  3 in total

1.  RECQL, a member of the RecQ family of DNA helicases, suppresses chromosomal instability.

Authors:  Sudha Sharma; Deborah J Stumpo; Adayabalam S Balajee; Cheryl B Bock; Peter M Lansdorp; Robert M Brosh; Perry J Blackshear
Journal:  Mol Cell Biol       Date:  2006-12-11       Impact factor: 4.272

2.  Unique and important consequences of RECQ1 deficiency in mammalian cells.

Authors:  Sudha Sharma; Robert M Brosh
Journal:  Cell Cycle       Date:  2008-01-30       Impact factor: 4.534

3.  The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation.

Authors:  Ramiro Mendoza-Maldonado; Valentina Faoro; Sailesh Bajpai; Matteo Berti; Federico Odreman; Marco Vindigni; Tamara Ius; Abdollah Ghasemian; Serena Bonin; Miran Skrap; Giorgio Stanta; Alessandro Vindigni
Journal:  Mol Cancer       Date:  2011-07-13       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.